Ticagrelor
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myocardial Infarction
Conditions
Myocardial Infarction
Trial Timeline
Oct 1, 2014 → Jan 1, 2016
NCT ID
NCT02292277About Ticagrelor
Ticagrelor is a pre-clinical stage product being developed by AstraZeneca for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02292277. Target conditions include Myocardial Infarction.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03492931 | Phase 1 | Completed |
| NCT03145194 | Phase 2 | UNKNOWN |
| NCT02341729 | Approved | Completed |
| NCT02292277 | Pre-clinical | Completed |
| NCT02282332 | Approved | Completed |
| NCT02071212 | Phase 2 | Completed |
| NCT01870921 | Approved | Completed |
Competing Products
20 competing products in Myocardial Infarction